Business
Board changes
Board changes.
About this update from Genedrive Plc
[{"type":"text","content":"\n\n \nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY GENEDRIVE PLC TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"MAR\").\n \nUPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \ngenedrive plc\n(\"genedrive\" or the \"Company\")\n \nBoard changes\n \ngenedrive plc (AIM: GDR), the near patient molecular diagnostics company announces the appointment of James Cheek as Chief Executive Officer (\"CEO\") and a Director of the Company. James will take up the positions today and will succeed David Budd, who has notified the Company of his intention to step down from the role with immediate effect.\n \nJames brings extensive commercial and operational experience at a senior level through a successful career with established diagnostic companies such as Cepheid, Beckman Coulter, and Roche Diagnostics, as well as serving as an executive board member of the British In Vitro Diagnostics Association (BIVDA). The Board believes James' experience, especially his extensive involvement in selling into the NHS, will be valuable as the Company expands its commercial footprint and opportunities within the UK and more widely.\n \nWe are also pleased to announce the appointment of Dr Gino Miele, Chief Scientific Officer at genedrive, to the Board as an Executive Director, with immediate effect. Gino has considerable experience in the development of molecular diagnostic technologies and systems and has been the R&D Director at genedrive since 2015 and its predecessor Epistem since 2011. Prior to that Gino has held associate director positions in personalised medicine at Wyeth and Pfizer. Gino has been a key driver in the development of the genedrive® system and the recent menu of pharmacogenetic tests.\n \nIan Gilham, Chairman of genedrive, commented: \"I am pleased to welcome James to the Company and look forward to working with him on the continued execution of our plans in commercialising our innovative Point-of-Care molecular diagnostic platform and tests. The focus of the Board remains on the development and commercialisation of novel Point-of-Care Molecular Diagnostic opportunities a...